Tag:

Cell Therapeutics

Latest Headlines

Latest Headlines

UPDATED: Cell Therapeutics lands myelofibrosis drug with $30M upfront

In addition to the $30 million upfront for the Singapore-based biotech, CEO Jim Bianco committed the company to an unspecified set of milestones for the treatment.

Cell Therapeutics calls retreat on bloodied pixantrone app

Two years after Cell Therapeutics ( $CTIC ) took one of the worst regulatory beatings of the decade at the time the FDA and its experts rejected the company's cancer drug pixantrone , the Seattle-based

Battered Cell Therapeutics pays $5M to in-license AML drug

Bruised and battered by its setback on pixantrone, Cell Therapeutics ( $CTIC ) is adding a new drug to its pipeline, paying $5 million upfront to license the North, Central and South American rights to

Cell Therapeutics raises $25M

Cell Therapeutics has raised $25 million by granting preferred stock and warrants to a single unnamed institutional investor. In a statement, the company says it intends to use the net proceeds from

Cell Therapeutics ($CTIC) appeals FDA decision on pixantrone

Cell Therapeutics said today that, as planned , it's submitted a formal appeal to the FDA regarding the agency's decision to reject pixantrone, an experimental treatment for relapsed/refractory

NASDAQ gives Cell Therapeutics ($CTIC) another warning

NASDAQ is giving Cell Therapeutics ( $CTIC ) another 180 days to regain compliance with Nasdaq's $1.00 minimum bid price rule. This is Cell Therapeutics second warning; In early May, Nasdaq notified

Cell Therapeutics gets OK to sell more shares

With its options running out, the financially strapped Cell Therapeutics ( CTIC ) has won shareholder approval for a plan to sell another 400,000 shares to keep the biotech afloat for now. Without

CTI will appeal FDA pixantrone ruling

Cell Therapeutics doesn't want to take 'no' for an answer. The developer, which recieved a harsh FDA rejection of pixantrone for relapsed/refractory aggressive non-Hodgkin's lymphoma, said today that

Which biotechs are the least efficient?

SmartTrend has looked at the biotech industry to determine which companies are the least efficient. Using revenue per employee (RPE)--a ratio useful when comparing a company against others in its

Struggling Cell Therapeutics raises $21M in stock sale

Just weeks after the FDA's embarrassing rejection of its cancer drug pixantrone , Seattle-based Cell Therapeutics ( CTIC ) said it was able to raise $21 million through the sale of preferred stock to